Tanja Obradovic: Another bevacizumab biosimilar entered the U.S. market
Tanja Obradovic, Oncology Medical Strategy Advisor at Mercurial AI, shared on LinkedIn:
“Just a few days ago, another bevacizumab biosimilar entered the U.S. market, as the FDA approved Jobevne (bevacizumab-nwgd), developed by Biocon Biologics. Jobevne is approved for several solid tumors as part of a chemotherapy backbone.
Metastatic colorectal cancer in combination with fluorouracil-based chemotherapy for first- or second-line treatment, and in combination with fluoropyrimidine-irinotecan or fluoropyrimidine-oxaliplatin-based chemotherapy for second-line treatment in patients who have progressed on a first-line bevacizumab-containing regimen.
Advanced non-squamous non-small cell lung cancer in combination with carboplatin and paclitaxel for first-line treatment, recurrent glioblastoma in adults, and metastatic renal cell carcinoma in combination with interferon alfa.
Advanced or metastatic cervical cancer in combination with paclitaxel and cisplatin, or paclitaxel and topotecan. For epithelial ovarian, fallopian tube, or primary peritoneal cancer, Jobevne is approved in combination with carboplatin and paclitaxel, followed by Jobevne as a single agent for stage III or IV disease following initial surgical resection.
In combination with paclitaxel, pegylated liposomal doxorubicin, or topotecan for platinum-resistant recurrent disease in patients who have received no more than two prior chemotherapy regimens. For platinum-sensitive recurrent disease, it is approved in combination with carboplatin and paclitaxel or carboplatin and gemcitabine, followed by Jobevne as a single agent.
Great news for patients, as the landscape of approved bevacizumab biosimilars in the U.S. continues to expand. Currently available options include Avzivi (by Bio-Thera Solutions), Vegzelma (by Celltrion Inc), Alymsys (by Amneal Pharmaceuticals), Zirabev (by Pfizer), and Mvasi (by Amgen).
Compared to other biosimilars uptake of these for bevacizumab in the US is high and over 80% (informative recent article on issues affecting adoption so this 6th newcomer to the list is certain to add value at the bedside.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023